Inner Mongolia Huazhou Pharmaceutical Co., Ltd. was established on 29th, September, 2017. The register address is North Project Zone of Duguitala Town Industrial Park of Hangjinqi of Ordos City, covering an area of 200000 square meters, with register capital of RMB 100 million Yuan. Inner Mongolia Huazhou Pharmaceutical Co., Ltd. is a holding subsidiary of Anhui Jinquan Biotechnology Co. Ltd. It is professional in production, research and operation of fine chemicals, medical intermediates and medical materials. In 2019, 19,000 tons of pharmaceutical and chemical intermediates were approved by Hangjinqi Development and Reform Commission, with a total investment of 438 million yuan. The project will be constructed in two phases, with a total investment of 270 million yuan in the first phase and 168 million yuan in the second phase.
The project makes full use of the industrial park's abundant raw material supporting resources, taking methanol, baking soda, caustic soda, lime, hydrochloric acid, sulfuric acid, urea and ethylene glycol, and the park's existing products as the main raw materials.
In the first phase, it is planned to build a production capacity of 1,800 tons/year of atorvastatin calcium intermediate (including methyl isobutylacetate (M1)1000 tons/year, intermediate parent nucleus (M4)800 tons/year) and spermine 6000 tons/year.
The technology for the project is mainly provided by the parent company. The same process applied in Anhui Jinquan Biotechnology Co. Ltd. has been large-scale production, the technology is mature. In addition, according to the characteristics of process production and operation requirements, the design of this project adopts the distributed control system DCS and local control to monitor and automatically control the process parameters and motor equipment in the production process, and its automatic control level has reached the advanced level of the same type of devices in China.
The first phase of the project includes production workshop 1, production Workshop 2, production workshop 3, production workshop 10, three Class A warehouse, one Class B warehouse, one Class C warehouse, one solid waste warehouse, one heavy drug warehouse, air compressed nitrogen freezing station, total transformer distribution power station, circulating water station, fire water station, comprehensive tank farm, LNG gas supply station, accident pool, research and development building, canteen, etc. The total construction area is 60,000 square meters.
The first phase of the project has been accepted by the experts of the Municipal Emergency Bureau at the end of May 2022, and the official trial production. After two months of continuous debugging and optimization, the large-scale production and sales of spermine and M1 products began in August.
In 2022 and 2023, the turnover is expected to reach 180 million yuan and 420 million yuan, and the net profit is expected to reach 20 million yuan and 50 million yuan respectively. The future development prospect of the company is positive.
